Data analysis
RP
Data were combined for patients randomized to receive guselkumab 100 mg Q4W or Q8W, as similar clinical efficacy and rates of RP were observed through Week 100 in DISCOVER-2, regardless of guselkumab dosing regimen [The associations between Week 8 change in DAPSA score as a continuous variable, DAPSA improvement greater than the median, DAPSA improvement more than the MCID (7.25), as well as achievement of DAPSA LDA (≤ 14), and the time-averaged changes in total PsA-modified vdH-S score from baseline to Weeks 52 and 100 were analyzed using multivariate mixed models for repeated measures accounting for known risk factors of RP including baseline age, sex, baseline PsA-modified vdH-S score, and baseline CRP level [